CancerPhase 1/2NCT03400332
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
A Phase 1/2 study testing BMS-986253, Nivolumab and Ipilimumab in people with Cancer and Melanoma, run by Bristol-Myers Squibb at 72 sites in 12 countries.
Trial summary
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers. Read more about this study
- Who is it for?
- Ages 18 years and older
- What is being tested?
- BMS-986253, Nivolumab and Ipilimumab
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 281 participants
- Where
- 72 sitesin 12 countries
- Study dates
- 12 Feb 2018to 4 Dec 2025
- Phase
- Phase 1/2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1
- At least 1 lesion accessible for biopsy
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
Who cannot join
- Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll)
- Participants with active, known or suspected autoimmune disease
- Participants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration
- Participants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS)
- Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy
- Other protocol defined inclusion/exclusion criteria could apply
Trial locations and contacts
72 sites in 12 countries.
72 sites in 12 countries
United States29 sites
Local Institution - 0004
Ann Arbor, Michigan, 48109
Local Institution - 0087
Atlanta, Georgia, 30322
Local Institution - 0100
Atlanta, Georgia, 30342
Local Institution - 0011
Austin, Texas, 78705
Local Institution - 0060
Boston, Massachusetts, 02215
Local Institution - 0012
Columbia, Maryland, 21044
Local Institution - 0010
Dallas, Texas, 75246
Local Institution - 0017
Eugene, Oregon, 97401
Local Institution - 0015
Fairfax, Virginia, 22031
Local Institution - 0014
Fort Worth, Texas, 76104-3927
Local Institution - 0009
Greenville, South Carolina, 29615
Local Institution - 0005
Hackensack, New Jersey, 07601
Local Institution - 0018
Houston, Texas, 77030
Local Institution - 0007
Lakewood, Colorado, 80228
Comprehensive Cancer Centers Of Nevada
Las Vegas, Nevada, 89169
Local Institution - 0099
Los Angeles, California, 90033
Local Institution - 0003
Lutherville, Maryland, 21093
Local Institution - 0101
Marietta, Georgia, 30060
Local Institution - 0032
New Brunswick, New Jersey, 08903
Local Institution - 0025
New York, New York, 10029
Local Institution - 0002
New York, New York, 10032
Local Institution - 0008
Norfolk, Virginia, 23502
Local Institution - 0028
Oklahoma City, Oklahoma, 73104
Local Institution - 0076
Omaha, Nebraska, 68130
Local Institution - 0001
Pittsburgh, Pennsylvania, 15213
Local Institution - 0058
Salt Lake City, Utah, 84112
Local Institution - 0006
San Antonio, Texas, 78240
Local Institution - 0059
Springdale, Arkansas, 72762
Local Institution - 0013
Tyler, Texas, 75702
Australia6 sites
Local Institution - 0096
Adelaide, South Australia, 5000
Local Institution - 0091
Ballarat Central, VIC 3350
Local Institution - 0090
Melbourne, Victoria, 3000
Local Institution - 0095
Melbourne, Victoria, 3004
Local Institution - 0097
Perth, Western Australia, 6009
Local Institution - 0088
Wollstonecraft, New South Wales, 2065
Canada6 sites
Local Institution - 0030
Edmonton, Alberta, T6G 1Z2
Local Institution - 0056
Montreal, Quebec, H2X 0A9
Local Institution - 0020
Toronto, Ontario, M5G 1Z5
Local Institution - 0055
Toronto, Ontario, M5G 2M9
Local Institution - 0029
Vancouver, British Columbia, V5Z 4E6
Local Institution - 0078
Victoria, British Columbia, V8R 6V5
Spain6 sites
Local Institution - 0045
Madrid, 28034
Local Institution - 0022
Madrid, 28040
Local Institution - 0023
Madrid, 28050
Local Institution - 0044
Málaga, 29010
Local Institution - 0021
Pamplona, 31008
Local Institution - 0047
Santiago de Compostela, 15706
France5 sites
Local Institution - 0067
Marseille, Bouches-du-Rhône, 13385
Local Institution - 0085
Nantes, 44000
Local Institution - 0068
Paris, 75010
Local Institution - 0102
Toulouse, 31059
Local Institution - 0069
Villejuif, 94800
Germany4 sites
Local Institution - 0034
Berlin, 12200
Local Institution - 0053
Hamburg, 20251
Local Institution - 0052
Mainz, Rhineland-Palatinate, 55131
Local Institution - 0054
Tübingen, Baden-Wurttemberg, 72076
Italy4 sites
Local Institution - 0043
Forlì, 47014
Local Institution - 0042
Milan, 20132
Local Institution - 0027
Naples, 80131
Local Institution - 0026
Rozzano-milano, 20089
Belgium3 sites
Local Institution - 0037
Brussels, 1200
Local Institution - 0036
Ghent, 9000
Local Institution - 0082
Kortrijk, 8500
Switzerland3 sites
Local Institution - 0040
Lausanne, 1011
Local Institution - 0041
Sankt Gallen, 9007
Local Institution - 0039
Zurich, 8091
United Kingdom3 sites
Local Institution - 0019
Birmingham, West Midlands, B15 2TH
Local Institution - 0083
Glasgow, Lanarkshire, G12 0YN
Local Institution - 0024
Manchester, Greater Manchester, M20 4BX
Poland2 sites
Local Institution - 0071
Krakow, 31-115
Local Institution - 0077
Warsaw, 02-781
About this study
Official title: A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
- Being tested
- BMS-986253, Nivolumab, Ipilimumab, Placebo
- Medical subject headings
- Neoplasms, Melanoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BMS-986253Drug
Specified dose on specified days
NivolumabBiological
Also called BMS-936558, Opdivo
Specified dose on specified days
IpilimumabBiological
Also called BMS-734016, YERVOY
Specified dose on specified days
PlaceboOther
Specified dose on specified days
| Study group | Role | What they receive |
|---|---|---|
| Part 1A: BMS-986253 + nivolumab | Experimental | Not described Receives: Drug: BMS-986253; Biological: Nivolumab |
| Part 1B: BMS-986253 + nivolumab | Experimental | Not described Receives: Drug: BMS-986253; Biological: Nivolumab |
| Part 1C: BMS-986253 + nivolumab + ipilimumab | Experimental | Not described Receives: Drug: BMS-986253; Biological: Nivolumab; Biological: Ipilimumab |
| Part 2A: BMS-986253 + nivolumab + ipilimumab | Experimental | Not described Receives: Drug: BMS-986253; Biological: Nivolumab; Biological: Ipilimumab |
| Part 2B: Placebo + nivolumab + ipilimumab | Placebo comparator | Not described Receives: Biological: Nivolumab; Biological: Ipilimumab; Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants Experiencing Adverse Events (AEs) - Part 1
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
This endpoint was prespecified in the protocol to include only participants in Part 1.
Measured: From first dose up to 100 days after last dose (up to 65 months)
Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 1
A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
This endpoint was prespecified in the protocol to include only participants in Part 1.
Measured: From first dose up to 100 days after last dose (up to 65 months)
Number of Participants Experiencing Dose Limiting Toxicities (DLTs) - Part 1
Dose-Limiting Toxicities (DLTs) are effects of a treatment that are serious enough to prevent an increase in dose of that treatment, as advised by the Dose Review Team. DLTs will be defined based on the incidence, intensity, and duration of AEs that are possibly related to study treatment. DLTs will include gastrointestinal, hepatic, hematologic, dermatologic, and other AEs.
This endpoint was prespecified in the protocol to include only participants in Part 1.
Measured: From first dose up to 100 days after last dose (up to 65 months)
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 1
Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
This endpoint was prespecified in the protocol to include only participants in Part 1.
Measured: From first dose up to 100 days after last dose (up to 65 months)
Number of Participants Who Died - Part 1
The number of participants who died due to any cause are summarized. This endpoint was prespecified in the protocol to include only participants in Part 1.
Measured: From first dose up to 100 days after last dose (up to 65 months)
Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 1
Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
This endpoint was prespecified in the protocol to include only participants in Part 1.
Measured: From first dose up to 30 days after last dose (up to 63 months)
Objective Response Rate (ORR) - Part 2
Objective Response Rate per blinded independent central review (BICR) is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. This endpoint was prespecified in the protocol to include only participants in Part 2.
Measured: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 22 months)
Secondary outcomes (22)
Objective Response Rate (ORR) - Part 1
Objective Response Rate per investigator is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. This endpoint was prespecified in the protocol to include only participants in Part 1.
Measured: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)
Duration of Response (DOR) - Part 1
DOR for a participant with a best overall response (BOR) of CR or PR is defined as the date of first response up to the date of the first objectively documented tumor progression by the investigator per RECIST v1.1 or death, whichever occurs first. Analysis computed using Kaplan-Meier method.
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =< 10 mm.
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm.
This endpoint was prespecified in the protocol to include only participants in Part 1.
Measured: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)
Maximum Concentration (Cmax) - Part 1
Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Measured: Cycle 1 Day 1
AUC(0-T)-Area Under Curve From Time Zero up to Last Quantifiable Concentration - Part 1
AUC (0-T) represents the observed exposure to a drug (area under the concentration curve) from first exposure until the last quantifiable concentration. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Measured: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Cycle 1 Day 1
AUC(TAU)-Area Under Curve in 1 Dosing Interval - Part 1
Area under the concentration-time curve in 1 dosing interval. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Measured: Cycle 1 Day 1
Observed Serum Concentration at the End of a Dosing Interval (Ctau) - Part 1
BMS-986253 observed serum concentration at the end of a dosing interval (Ctau). Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.
1 cycle=28 days for all Arms/Groups except Cycles 1 and 2 (1 cycle=42 days) in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group
Measured: Cycle 1 Day 1
Total Body Clearance (CLT) - Part 1
Clearance is the rate of elimination of BMS-986253 from the blood calculated as the rate of elimination divided by serum concentration. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Measured: Cycle 1 Day 1
Average Serum Concentration Over a Dosing Interval (Css-avg) - Part 1
BMS-986253 Average concentration over a dosing interval (\[AUC(TAU)/tau\] (Css-avg) at steady state. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Measured: Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1
AUC Accumulation Index (AI_AUC) - Part 1
AUC Accumulation Index is defined as the ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Measured: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Cmax Accumulation Index (AI_Cmax) - Part 1
BMS-986253 Cmax accumulation index (AI_Cmax). Ratio of an exposure measure at steady state to that after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Measured: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Ctau Accumulation Index (AI_Ctau) - Part 1
Ctau is the observed serum concentration at the end of a dosing interval. Ctau accumulation index (AI_Ctau) is the ratio of an exposure measure at steady state to that after the first dose. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. Ctau was reported on non-compartmental analysis day, which is on Cycle 1 Day1, Cycle 2 Day 1, Cycle 3 Day 1, or Cycle 4 Day 1 based on data available.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Measured: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Effective Elimination (T-HALFeff) - Part 1
BMS-986253 effective elimination (T-HALFeff) that explains the degree of accumulation observed for a specific exposure measure. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Note: C2D1, C3D1, C4D1 were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Measured: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Time to Maximum Concentration (Tmax) - Part 1
Tmax is defined as the time it takes for a drug to reach the maximum concentration (Cmax) after administration of a drug.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Measured: Cycle 1 Day 1
Serum Trough Concentration (Ctrough) - Part 1
A serum trough concentration (Ctrough) is the concentration reached by a drug immediately before the next dose is administered. Serum trough concentrations (Ctrough) of BMS-986253 will be summarized with descriptive statistics by treatment and visit.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Note: The timepoints listed were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Measured: C1D15, C1D29, C2D1, C2D9, C2D15, C3D1, C4D1, C4D15, C5D1, C7D1, C9D1, C10D1, C14D1, C20D1, and C26D1
Number of Participants With Anti-Drug Antibodies (ADA) - Part 1
Blood samples were evaluated for development of Anti-Drug Antibody (ADA) by a validated electrochemiluminescent (ECL) immunoassay. Baseline is defined as first dose.
ADA-positive subject: A subject with at least one ADA positive-sample relative to baseline at any time after initiation of treatment.
Persistent Positive (PP): ADA-positive sample at 2 or more consecutive time points, where the first and last ADA-positive samples are at least 16 weeks apart
Not PP-Last Sample Positive: Not persistent positive with ADA-positive sample at the last sampling time point
Other Positive: Not persistent positive but some ADA-positive samples with the last sample being negative
Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected
ADA-negative subject: A subject with no ADA-positive sample after the initiation of treatment.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Measured: C1D1, C1D2, C1D8, C1D15, C1D22, C2D1, C2D2, C2D8, C2D15, C3D1, C4D1, C4D2, C4D8, C4D15, C4D22, C5D1, C9D1, C14D1, C20D1, C26D1, C32D1, C38D1, 30-day follow-up, 100-day follow-up
Change From Baseline in Interleukin 8 (IL-8)- Part 1
Change from baseline in IL-8 measured in pg/mL. Baseline is defined as first dose.
1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)
Note: Some timepoints were partial samplings only as pre-specified in the protocol and did not include a sampling for each arm.
Measured: C1D2, C1D8, C1D15, C1D22, C1D29, C1D36, C2D1, C2D2, C2D8, C2D15, C2D22, C2D29, C3D1, C3D2, C3D8, C4D1, C4D2, C4D8, C4D15, C4D22, C5D1, C7D1, C8D1, C9D1, C10D1, C11D1, C14D1, C16D1, C17D1, C20D1, C23D1, C26D1, at last dose, and 100 days post last dose
Progression Free Survival (PFS) - Part 2
Progression free survival (PFS) is defined for all randomized participants as the date from randomization to the date of the documentation of disease progression by BICR or death due to any cause, whichever is earlier.
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
This endpoint was prespecified in the protocol to include only participants in Part 2.
Measured: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 22 months)
Number of Participants Experiencing Adverse Events (AEs) - Part 2
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
This endpoint was prespecified in the protocol to include only participants in Part 2.
Measured: From first dose up to 100 days after last dose (up to 25 months)
Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 2
A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.
Measured: From first dose up to 100 days after last dose (up to 25 months)
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 2
Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Measured: From first dose up to 100 days after last dose (up to 25 months)
Number of Participants Who Died - Part 2
The number of participants who died due to any cause are summarized.
Measured: From first dose up to 100 days after last dose (up to 25 months)
Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 2
Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
This endpoint was prespecified in the protocol to include only participants in Part 2.
Measured: From first dose up to 30 days after last dose (up to 23 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jan 2018
- Study start12 Feb 2018
- Primary completion26 Apr 2024
- Study completion4 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 281 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03400332
- Sponsor's protocol ID
- CA027-002
- Other IDs
- 2023-509061-20, 2023
- Status last verified
- Jan 2026
- First submitted
- 12 Jan 2018
- Last updated
- 24 Feb 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Cai S, Wei X, Li Q, Jiang Z, Li L. Smart materials in pharmacological drug development: Neutrophils and its constituents for drug delivery and consequent antitumor effects. Mol Immunol. 2025 Jul;183:18-32. doi: 10.1016/j.molimm.2025.04.010. Epub 2025 May 2.
PubMed 40318595
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
- ClinicalTrials.gov ID
- NCT03400332
- Acronym / sponsor ID
- CA027-002
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 281 participants (actual)
- Lead sponsor
- Bristol-Myers SquibbIndustry (pharma, biotech, devices)
- Study start
- 12 Feb 2018 (actual)
- Primary completion
- 26 Apr 2024 (actual)
- Study completion
- 4 Dec 2025 (actual)
- First posted
- 17 Jan 2018 (actual)
- Results
- Posted 19 Jun 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Part 1A: BMS-986253 + nivolumab | Experimental | Drug: BMS-986253, Biological: Nivolumab |
| Part 1B: BMS-986253 + nivolumab | Experimental | Drug: BMS-986253, Biological: Nivolumab |
| Part 1C: BMS-986253 + nivolumab + ipilimumab | Experimental | Drug: BMS-986253, Biological: Nivolumab, Biological: Ipilimumab |
| Part 2A: BMS-986253 + nivolumab + ipilimumab | Experimental | Drug: BMS-986253, Biological: Nivolumab, Biological: Ipilimumab |
| Part 2B: Placebo + nivolumab + ipilimumab | Placebo comparator | Biological: Nivolumab, Biological: Ipilimumab, Other: Placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1
- At least 1 lesion accessible for biopsy
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
Key exclusion criteria (6 listed)
- Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll)
- Participants with active, known or suspected autoimmune disease
- Participants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration
- Participants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS)
- Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BMS-986253Specified dose on specified days | Drug | Part 1A: BMS-986253 + nivolumab, Part 1B: BMS-986253 + nivolumab, Part 1C: BMS-986253 + nivolumab + ipilimumab, Part 2A: BMS-986253 + nivolumab + ipilimumab |
| NivolumabAlso: BMS-936558, OpdivoSpecified dose on specified days | Biological | Part 1A: BMS-986253 + nivolumab, Part 1B: BMS-986253 + nivolumab, Part 1C: BMS-986253 + nivolumab + ipilimumab, Part 2A: BMS-986253 + nivolumab + ipilimumab, Part 2B: Placebo + nivolumab + ipilimumab |
| IpilimumabAlso: BMS-734016, YERVOYSpecified dose on specified days | Biological | Part 1C: BMS-986253 + nivolumab + ipilimumab, Part 2A: BMS-986253 + nivolumab + ipilimumab, Part 2B: Placebo + nivolumab + ipilimumab |
| PlaceboSpecified dose on specified days | Other | Part 2B: Placebo + nivolumab + ipilimumab |
Primary outcome
Number of Participants Experiencing Adverse Events (AEs) - Part 1
Time frame: From first dose up to 100 days after last dose (up to 65 months)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 1.
Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 1
Time frame: From first dose up to 100 days after last dose (up to 65 months)
A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event. This endpoint was prespecified in the protocol to include only participants in Part 1.
Number of Participants Experiencing Dose Limiting Toxicities (DLTs) - Part 1
Time frame: From first dose up to 100 days after last dose (up to 65 months)
Dose-Limiting Toxicities (DLTs) are effects of a treatment that are serious enough to prevent an increase in dose of that treatment, as advised by the Dose Review Team. DLTs will be defined based on the incidence, intensity, and duration of AEs that are possibly related to study treatment. DLTs will include gastrointestinal, hepatic, hematologic, dermatologic, and other AEs. This endpoint was prespecified in the protocol to include only participants in Part 1.
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 1
Time frame: From first dose up to 100 days after last dose (up to 65 months)
Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This endpoint was prespecified in the protocol to include only participants in Part 1.
Number of Participants Who Died - Part 1
Time frame: From first dose up to 100 days after last dose (up to 65 months)
The number of participants who died due to any cause are summarized. This endpoint was prespecified in the protocol to include only participants in Part 1.
Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 1
Time frame: From first dose up to 30 days after last dose (up to 63 months)
Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 1.
Objective Response Rate (ORR) - Part 2
Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 22 months)
Objective Response Rate per blinded independent central review (BICR) is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. This endpoint was prespecified in the protocol to include only participants in Part 2.
22 secondary outcomes
Objective Response Rate (ORR) - Part 1
Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)
Duration of Response (DOR) - Part 1
Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)
Maximum Concentration (Cmax) - Part 1
Time frame: Cycle 1 Day 1
AUC(0-T)-Area Under Curve From Time Zero up to Last Quantifiable Concentration - Part 1
Time frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Cycle 1 Day 1
AUC(TAU)-Area Under Curve in 1 Dosing Interval - Part 1
Time frame: Cycle 1 Day 1
Observed Serum Concentration at the End of a Dosing Interval (Ctau) - Part 1
Time frame: Cycle 1 Day 1
Total Body Clearance (CLT) - Part 1
Time frame: Cycle 1 Day 1
Average Serum Concentration Over a Dosing Interval (Css-avg) - Part 1
Time frame: Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1
AUC Accumulation Index (AI_AUC) - Part 1
Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Cmax Accumulation Index (AI_Cmax) - Part 1
Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Ctau Accumulation Index (AI_Ctau) - Part 1
Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Effective Elimination (T-HALFeff) - Part 1
Time frame: Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1
Time to Maximum Concentration (Tmax) - Part 1
Time frame: Cycle 1 Day 1
Serum Trough Concentration (Ctrough) - Part 1
Time frame: C1D15, C1D29, C2D1, C2D9, C2D15, C3D1, C4D1, C4D15, C5D1, C7D1, C9D1, C10D1, C14D1, C20D1, and C26D1
Number of Participants With Anti-Drug Antibodies (ADA) - Part 1
Time frame: C1D1, C1D2, C1D8, C1D15, C1D22, C2D1, C2D2, C2D8, C2D15, C3D1, C4D1, C4D2, C4D8, C4D15, C4D22, C5D1, C9D1, C14D1, C20D1, C26D1, C32D1, C38D1, 30-day follow-up, 100-day follow-up
Change From Baseline in Interleukin 8 (IL-8)- Part 1
Time frame: C1D2, C1D8, C1D15, C1D22, C1D29, C1D36, C2D1, C2D2, C2D8, C2D15, C2D22, C2D29, C3D1, C3D2, C3D8, C4D1, C4D2, C4D8, C4D15, C4D22, C5D1, C7D1, C8D1, C9D1, C10D1, C11D1, C14D1, C16D1, C17D1, C20D1, C23D1, C26D1, at last dose, and 100 days post last dose
Progression Free Survival (PFS) - Part 2
Time frame: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 22 months)
Number of Participants Experiencing Adverse Events (AEs) - Part 2
Time frame: From first dose up to 100 days after last dose (up to 25 months)
Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 2
Time frame: From first dose up to 100 days after last dose (up to 25 months)
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 2
Time frame: From first dose up to 100 days after last dose (up to 25 months)
Number of Participants Who Died - Part 2
Time frame: From first dose up to 100 days after last dose (up to 25 months)
Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 2
Time frame: From first dose up to 30 days after last dose (up to 23 months)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 40318595Cai S, Wei X, Li Q, Jiang Z, Li L. Smart materials in pharmacological drug development: Neutrophils and its constituents for drug delivery and consequent antitumor effects. Mol Immunol. 2025 Jul;183:18-32. doi: 10.1016/j.molimm.2025.04.010. Epub 2025 May 2.
- BMS Clinical Trial InformationLink provided by the sponsor.
- BMS Clinical Trial Patient RecruitingLink provided by the sponsor.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol-Myers Squibb study director
Bristol-Myers Squibb
72 sites in 12 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing BMS-986253, Nivolumab and Ipilimumab in people with Cancer and Melanoma, run by Bristol-Myers Squibb at 72 sites in 12 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 72 sites in United States, Australia, Canada, Spain, France and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 19 Jun 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants Experiencing Adverse Events (AEs) - Part 1 (time frame: From first dose up to 100 days after last dose (up to 65 months)). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03400332, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2026.